[
  {
    "trial": "T004",
    "source": "library",
    "arms": {
      "Coadministration group (propofol + ketamine)": {
        "randomized": "20",
        "analysed": "19"
      },
      "Propofol group (propofol alone)": {
        "randomized": "20",
        "analysed": "20"
      }
    },
    "depression": [],
    "pain": [],
    "adverse_events": [
      {
        "window": "intraoperative",
        "location": "Results, second paragraph",
        "values": {
          "Coadministration group (propofol + ketamine)": {
            "agitation": "0",
            "any_ae": "0"
          },
          "Propofol group (propofol alone)": {
            "agitation": "1",
            "any_ae": "1"
          }
        }
      },
      {
        "window": "emergence",
        "location": "Results, paragraph on mood, cognition and perception; abstract",
        "values": {
          "Coadministration group (propofol + ketamine)": {
            "dissociation": "0"
          },
          "Propofol group (propofol alone)": {
            "dissociation": "4"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Randomized 20 per arm (Methods). Analysed n: Propofol 20, Coadministration 19 in the abstract, Table 1, Fig. 1 and Tables 2-3 (the missing Coadministration patient is not explained); the Fig. 2 caption gives them the other way round (Propofol n = 19, Coadministration n = 20). Depression: the 'depressed/elated' mood VAS (before surgery and 15 min after arrival in recovery) is shown only in Fig. 2 (median, 25th-75th percentiles) with no printed values, so no entries; the text says postoperative mood scores were higher with coadministration for all six mood states. Pain: no numbers at day 1 or 2; the text gives only P values for first-postoperative-day pain at rest and on activity and hydrocodone use, and Table 3 gives time (days) to normalization, median (quartiles): Propofol pain at rest 5 (4, 5), on activity 4 (4, 4), hydrocodone 4 (4, 4); Coadministration 3 (2, 4), 3 (2, 4), 3 (2, 4). Pain VAS on arrival in Phase 2 recovery (day 0, not extracted): Propofol 20 [2.0-20.0], Coadministration 0 [0.0-0.0], median [quartiles]. AEs: the only intraoperative adverse event was 'transient restlessness' in the Propofol group ('there was only one event', printed in words), coded agitation and any_ae; the Coadministration zeros follow from that statement rather than a printed 0. Mild perceptual changes (VAS <= 20) in surroundings, time, colors and sounds in 'four' Propofol patients on arrival in recovery, gone 30 min after surgery, coded dissociation (derealization-type, window emergence); the abstract says coadministration produced no perceptual changes, which gives its 0. No changes in suspicion, weird feeling or thought process in either group. No enrollment period or registration given."
  },
  {
    "trial": "T005",
    "source": "library",
    "arms": {
      "Group A (propofol, fentanyl, ketamine)": {
        "randomized": "35",
        "analysed": "35"
      },
      "Group B (propofol, fentanyl)": {
        "randomized": "35",
        "analysed": "35"
      }
    },
    "depression": [
      {
        "measure": "Hamilton Depression Rating (HDR) score, 21 items",
        "day": -1,
        "form": "mean_sd",
        "location": "Results, HDR paragraph (also abstract)",
        "values": {
          "Group A (propofol, fentanyl, ketamine)": {
            "mean": "12.7",
            "sd": "5.4"
          },
          "Group B (propofol, fentanyl)": {
            "mean": "12.3",
            "sd": "6.0"
          }
        }
      },
      {
        "measure": "Hamilton Depression Rating (HDR) score, 21 items",
        "day": 1,
        "form": "mean_sd",
        "location": "Results, HDR paragraph (also abstract)",
        "values": {
          "Group A (propofol, fentanyl, ketamine)": {
            "mean": "9.9",
            "sd": "4.1"
          },
          "Group B (propofol, fentanyl)": {
            "mean": "14.4",
            "sd": "3.8"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Results, last paragraph",
        "values": {
          "Group A (propofol, fentanyl, ketamine)": {
            "psychiatric_any": "5"
          },
          "Group B (propofol, fentanyl)": {
            "psychiatric_any": "8"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Group C (25 non-depressed controls, not randomized) left out. 35 per arm randomized and analysed (Methods, Table 1, outcome denominators 'of 35'); no per-time n printed. Baseline HDR was measured 2 days before surgery (day -1). Day 3 HDR is shown only in Fig. 1 (box plots, no printed values; text: no significant difference). Count not entered (its time is not stated, and each measure and time takes one entry): 'Eight (23%) of 35 patients in Group B were up more than 5 points in HDR score after surgery', and 'no patients' in Group A; HDR was measured on days 1 and 3. Table 2 gives HDR item scores (mean +/- SD) before and the day after surgery (e.g., depressed mood after surgery 0.8 +/- 0.8 vs 2.1 +/- 1.0); items, not the total, so not entered. Pain: VAS printed only at 8 h (26.6 +/- 8.7 vs 34.3 +/- 12.0) and 16 h (24.9 +/- 8.2 vs 31.1 +/- 8.8), outside 18-30 h; 24 h and POD 1-2 values are only in Fig. 2. AEs: postoperative confusion by CAM (checked daily to day 7), 5 (14%) vs 8 (23%), coded psychiatric_any; the authors analyse it as 'psychosis emergence or confusion'. Not coded: ventricular ectopic rhythm 1 vs 2, hypotension at induction 2 vs 2. No enrollment dates or registration given."
  },
  {
    "trial": "T006",
    "source": "library",
    "arms": {
      "Placebo group": {
        "randomized": null,
        "analysed": "15"
      },
      "Single S(+)-ketamine group": {
        "randomized": null,
        "analysed": "15"
      },
      "Repeated S(+)-ketamine group": {
        "randomized": null,
        "analysed": "15"
      }
    },
    "depression": [
      {
        "measure": "Mood adjective choice after awakening (incl. 'depressed/euphoric', 'happy/sad')",
        "day": 0,
        "form": "count",
        "definition": "chose the adjective 'depressed' (from the pair depressed/euphoric) after awakening; patients chose an adjective only if it described their mood",
        "location": "Table 2, Status of mood after awakening, Depressed/euphoric row",
        "values": {
          "Placebo group": {
            "events": "0",
            "n": "15"
          },
          "Single S(+)-ketamine group": {
            "events": "0",
            "n": "15"
          },
          "Repeated S(+)-ketamine group": {
            "events": "0",
            "n": "15"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Table 2, Side effects attributable to ketamine",
        "values": {
          "Placebo group": {
            "psychiatric_any": "0"
          },
          "Single S(+)-ketamine group": {
            "psychiatric_any": "0"
          },
          "Repeated S(+)-ketamine group": {
            "psychiatric_any": "0"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": null,
    "note": "Per-arm randomized numbers are not printed: 52 enrolled; 2 withdrawn (arm not stated: epidural catheter failure, Bromage score > 2); 2 placebo and 3 single S(+)-ketamine patients excluded; 15 per arm analysed (Table 1 n row; Table 2 footnote: n = number of patients per group). Depression: Table 2 cells count patients choosing the first/second adjective (Placebo, Single, Repeated): Depressed/euphoric 0/0, 0/0, 0/8; Happy/sad 0/0, 0/0, 8/0, so 'sad' was 0, 0, 0 as well; the entry uses 'depressed'. Pain: VAS at awakening, 3, 6 and 24 h only in Fig. 1 (box plots), patients needing additional analgesics only in Fig. 2, and cumulative diclofenac and dextropropoxyphene at 24 h only in Fig. 3; no printed values. AEs: at each evaluation (awakening, 3, 6, 24 h) patients were asked about psychological effects, hallucinations or dreams; Table 2 'side effects attributable to ketamine' noted by patient 0, 0, 0 and by anesthesiologist 0, 0, 0, coded psychiatric_any (text: no psychotomimetic side effects). Not coded: hypotension 2, 0, 1; nausea/vomiting 5, 4, 3. No enrollment dates or registration given."
  },
  {
    "trial": "T011",
    "source": "library",
    "arms": {
      "K group": {
        "randomized": "60",
        "analysed": "60"
      },
      "C group (0.9% saline)": {
        "randomized": "60",
        "analysed": "60"
      }
    },
    "depression": [
      {
        "measure": "PHQ-9",
        "day": -1,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K group": {
            "mean": "4.02",
            "sd": "0.13"
          },
          "C group (0.9% saline)": {
            "mean": "3.63",
            "sd": "0.14"
          }
        }
      },
      {
        "measure": "PHQ-9",
        "day": 1,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K group": {
            "mean": "2.68",
            "sd": "0.73"
          },
          "C group (0.9% saline)": {
            "mean": "3.37",
            "sd": "0.91"
          }
        }
      },
      {
        "measure": "PHQ-9",
        "day": 5,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K group": {
            "mean": "2.28",
            "sd": "0.61"
          },
          "C group (0.9% saline)": {
            "mean": "2.92",
            "sd": "0.63"
          }
        }
      }
    ],
    "pain": [
      {
        "measure": "VAS score",
        "day": 1,
        "form": "mean_sd",
        "location": "Table 1",
        "values": {
          "K group": {
            "mean": "2.17",
            "sd": "0.24",
            "n": "60"
          },
          "C group (0.9% saline)": {
            "mean": "3.75",
            "sd": "0.42",
            "n": "60"
          }
        }
      }
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {
      "start": "2014-03",
      "end": "2014-09"
    },
    "registration": {
      "number": "ChicTR-OCC-14004280",
      "date": null
    },
    "note": "Table 2 prints PHQ-9 as 'mean + SD' ('+' for '+/-'; Methods: data are mean +/- SD). Its rows are C then K, as the per-group F values in the text show (C F = 2.17, K F = 14.67). The preoperative value was taken 1 day before surgery (day -1). Table 2 gives no n; Table 3's category counts total 60 per arm at each time. Counts not entered (each measure and time takes one entry, and the means were used), Table 3, PHQ-9 category, C vs K: before surgery 0-4: 38 vs 36, 5-10: 22 vs 23, >10: 0 vs 1; day 1 0-4: 43 vs 53, 5-10: 17 vs 7, >10: 0.00 vs 0.00; day 5 0-4: 49 vs 54, 5-10: 11 vs 6, >10: 0.00 vs 0.00 (Table 3 percentages are shares of each row). Discussion: PHQ-9 >= 5 ('depressed mood') before surgery in 24 K and 22 C patients, on day 1 in 7 K and 17 C. Pain: VAS from Table 1 (scale range not stated); day 5 VAS (1.12 +/- 0.87 vs 1.88 +/- 0.01) not extracted. AEs: only nausea (day 1: 12 vs 13; day 5: 0 vs 0) and insomnia (day 1: 10 vs 9; day 5: 8 vs 8) reported; no psychotomimetic events reported, so none coded. Enrollment dates from Methods ('between March 2014 and September 2014'); registration printed as 'ChicTR-OCC-14004280' beside the ethics number, no date."
  },
  {
    "trial": "T015",
    "source": "library",
    "arms": {
      "Ketamine group": {
        "randomized": null,
        "analysed": "162"
      },
      "Saline group": {
        "randomized": null,
        "analysed": "163"
      }
    },
    "depression": [
      {
        "measure": "EPDS",
        "day": 3,
        "form": "mean_sd",
        "location": "Table 4",
        "values": {
          "Ketamine group": {
            "mean": "7.2",
            "sd": "3.9",
            "n": "162"
          },
          "Saline group": {
            "mean": "7.2",
            "sd": "4.2",
            "n": "163"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 42,
        "form": "mean_sd",
        "location": "Table 4",
        "values": {
          "Ketamine group": {
            "mean": "5.6",
            "sd": "3.9",
            "n": "162"
          },
          "Saline group": {
            "mean": "5.7",
            "sd": "4.3",
            "n": "163"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "intraoperative",
        "location": "Table 3, 5 min after dosing",
        "values": {
          "Ketamine group": {
            "hallucination": "37",
            "dizziness": "113",
            "visual": "31"
          },
          "Saline group": {
            "hallucination": "0",
            "dizziness": "16",
            "visual": "0"
          }
        }
      },
      {
        "window": "intraoperative",
        "location": "Table 3, 15 min after dosing",
        "values": {
          "Ketamine group": {
            "hallucination": "8",
            "dizziness": "79",
            "visual": "14"
          },
          "Saline group": {
            "hallucination": "0",
            "dizziness": "10",
            "visual": "1"
          }
        }
      },
      {
        "window": "intraoperative",
        "location": "Table 3, out of operation room",
        "values": {
          "Ketamine group": {
            "hallucination": "3",
            "dizziness": "17",
            "visual": "4"
          },
          "Saline group": {
            "hallucination": "0",
            "dizziness": "8",
            "visual": "3"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2015-10-08",
      "end": "2016-03-10"
    },
    "registration": {
      "number": "ChiCTR-IPR-15007159",
      "date": null
    },
    "note": "330 enrolled and randomized 1:1; per-arm randomized numbers are only in the flow chart (Fig. 1), which is not printed. 1 missed the 3-day visit and 4 were lost by 6 weeks; 325 analysed (162 vs 163 in every table header). Day 42 = '6 week postpartum'. Not entered (each measure and time takes one entry, and the means were used): the primary outcome, occurrence of postpartum depression (EPDS >= 10), Table 4: day 3, 41 (25.3%) vs 46 (28.2%); 6 weeks, 26 (16.0%) vs 29 (17.8%). Pain: NRS only at 3 days, median (range) 4 (0-7) vs 4 (0-8), and 6 weeks, 1 (0-8) vs 2 (0-9); not days 1-2, not entered. AEs: Table 3 counts patients at each of three intraoperative checks (5 and 15 min after dosing, and just before leaving the operating room); a patient can appear at more than one, so the three entries are not to be summed. Diplopia coded visual. Not coded (ketamine/saline at 5 min, 15 min, leaving): vomiting 3/1, 7/1, 1/2; headache 8/1, 4/0, 3/0; drowsiness 71/4, 26/2, 5/1; Ramsay > 3 15/0, 0/0, 0/0. The Discussion says side effects were not fully documented after the operating room. Enrollment dates from Methods ('conducted from October 8, 2015 to March 10, 2016'); registration has no date."
  },
  {
    "trial": "T019",
    "source": "library",
    "arms": {
      "Ketamine": {
        "randomized": "50",
        "analysed": "44"
      },
      "Placebo (0.9% saline)": {
        "randomized": "50",
        "analysed": "46"
      }
    },
    "depression": [],
    "pain": [],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Table 3 and its footnote",
        "values": {
          "Ketamine": {
            "hallucination": "2",
            "dizziness": "5",
            "any_ae": "5"
          },
          "Placebo (0.9% saline)": {
            "hallucination": "0",
            "dizziness": "1",
            "any_ae": "3"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2014-10",
      "end": "2018-01"
    },
    "registration": {
      "number": "NCT02452060",
      "date": null
    },
    "note": "CONSORT (Fig. 1): 50 allocated per arm; 5 ketamine and 3 placebo patients withdrew consent before the drug; 1 per arm excluded for surgical complications; analysed 44 vs 46 (tables print 'nU44'/'nU46'). Depression: BDI and MADRS (baseline, POD 1, 2, 7) are shown only in Fig. 3 (mean and bootstrap SE), with no printed values, so no entries; text: no group differences (baseline-adjusted). Pain: VAS and SF-MPQ (PACU, POD 1, 2, 7) only in Fig. 2. The abstract's 'mean difference = 2.2 (95% bootstrap CI 2.9 to 1.6)' is the ketamine group's own decrease in the SF-MPQ affective subscale by POD 2 (minus signs apparently lost), not a between-arm difference, so not entered. Opioid use is reported only for the whole hospital stay (Table 2, median [IQR], mg/kg morphine equivalents: 0.25 [0.43 to 0.69] vs 0.26 [0.45 to 0.86], medians outside their printed IQRs); not day 1 or 2, not entered. AEs: Table 3 gives no timing; the drug was given in the PACU after surgery, hence window postoperative. 'Visual hallucinations' coded hallucination, 'Dizziness/lightheadedness' coded dizziness; any_ae from the footnote ('Three patients in the placebo group and five in the ketamine group complained of side effects', in words). Not coded: euphoria 2 vs 0, dysphoria 2 vs 0, nausea 2 vs 2, headache 1 vs 0; the Discussion counts 'five cases of mild psychiatric effects such as euphoria and dysphoria' in the ketamine group (5/44). Enrollment dates from the abstract's Setting line (the Results give none); registration has no date."
  },
  {
    "trial": "T025",
    "source": "library",
    "arms": {
      "Ketamine group": {
        "randomized": "41",
        "analysed": "41"
      },
      "Placebo group (normal saline)": {
        "randomized": "43",
        "analysed": "43"
      }
    },
    "depression": [
      {
        "measure": "MADRS (also at discharge)",
        "day": -1,
        "form": "median_iqr",
        "location": "Table 1",
        "values": {
          "Ketamine group": {
            "median": "28",
            "q1": "26",
            "q3": "31",
            "n": "41"
          },
          "Placebo group (normal saline)": {
            "median": "27",
            "q1": "25",
            "q3": "31",
            "n": "43"
          }
        }
      },
      {
        "measure": "MADRS (also at discharge)",
        "day": 2,
        "form": "mean_sd",
        "location": "Results, Primary and Secondary Outcomes, text",
        "values": {
          "Ketamine group": {
            "mean": "16",
            "sd": "9"
          },
          "Placebo group (normal saline)": {
            "mean": "21",
            "sd": "9"
          }
        }
      },
      {
        "measure": "MADRS (also at discharge)",
        "day": 3,
        "form": "count",
        "definition": "response: MADRS reduction ≥50% from baseline (counts responders, not participants with depression)",
        "location": "Table 3",
        "values": {
          "Ketamine group": {
            "events": "17",
            "n": "41"
          },
          "Placebo group (normal saline)": {
            "events": "7",
            "n": "43"
          }
        }
      },
      {
        "measure": "PHQ-9 (also at discharge)",
        "day": -1,
        "form": "median_iqr",
        "location": "Table 1",
        "values": {
          "Ketamine group": {
            "median": "13",
            "q1": "11",
            "q3": "15",
            "n": "41"
          },
          "Placebo group (normal saline)": {
            "median": "13",
            "q1": "12",
            "q3": "15",
            "n": "43"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Table 3, Psychiatric outcomes (postoperative day 3)",
        "values": {
          "Ketamine group": {
            "dissociation": "3"
          },
          "Placebo group (normal saline)": {
            "dissociation": "1"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2017-07-05",
      "end": "2018-08-21"
    },
    "registration": {
      "number": "NCT03086148",
      "date": null
    },
    "note": "ITT: all 84 analysed after imputing missing postoperative scores (baseline values for 9 at day 1, 7 at day 2 and 2 at day 3; last observation for 3 at discharge), so no per-time n is printed for the day 2 means. Baseline (Table 1) was 1 day before surgery. Day 2 MADRS '16 [SD = 9] vs 21 [SD = 9]' are means (Fig. 2 plots means with SD). Day 1 MADRS and all postoperative PHQ-9 values are only in Fig. 2 (no printed values; PHQ-9 P = .036 at day 2 and .015 at day 3). Not entered (one entry per measure and time, or no fixed day): MADRS reduction from baseline at day 3, '11 vs 7, respectively; 95% CI, -0.51 to 7.96' (summary statistic not stated); response at day 2, 43.9% vs 20.0% (percentages only); at discharge (median stay 7 vs 8 days), Table 3: response 16 (39.0) vs 9 (20.9), remission (MADRS ≤10) 12 (29.3) vs 3 (7.0). The primary RR differs by place (text 2.25, abstract 2.51, Table 3 2.55; CI 1.18-5.50 in each). Pain: only cumulative severe pain (NRS ≥5) over the first 3 days, 19 (47.5) vs 17 (39.5), not at 24 or 48 h, so not entered (47.5% does not match 19/41). AEs: Table 3 psychiatric outcomes at day 3; dissociative symptoms (CADSS ≠ 0) coded dissociation. Not coded: manic symptoms (YMRS ≥5) 2 (4.9) vs 1 (2.3); psychotic symptoms (4 BPRS items incl. hallucinations ≥5) 3 (7.3) vs 4 (9.3); delirium on day 1 (CAM-ICU) 1 (2.4) vs 3 (7.0)."
  },
  {
    "trial": "T028",
    "source": "library",
    "arms": {
      "Control group (normal saline)": {
        "randomized": "100",
        "analysed": "100"
      },
      "Racemic ketamine group": {
        "randomized": "102",
        "analysed": "102"
      },
      "S-ketamine group": {
        "randomized": "101",
        "analysed": "101"
      }
    },
    "depression": [
      {
        "measure": "HAMD-17",
        "day": -1,
        "form": "mean_sd",
        "location": "Table 3",
        "values": {
          "Control group (normal saline)": {
            "mean": "17.0",
            "sd": "2.2",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "17.0",
            "sd": "2.2",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "16.8",
            "sd": "2.3",
            "n": "101"
          }
        }
      },
      {
        "measure": "HAMD-17",
        "day": 3,
        "form": "mean_sd",
        "location": "Table 3",
        "values": {
          "Control group (normal saline)": {
            "mean": "16.4",
            "sd": "2.0",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "13.2",
            "sd": "2.5",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "11.4",
            "sd": "2.2",
            "n": "101"
          }
        }
      },
      {
        "measure": "HAMD-17",
        "day": 7,
        "form": "mean_sd",
        "location": "Table 3",
        "values": {
          "Control group (normal saline)": {
            "mean": "11.2",
            "sd": "3.6",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "10.5",
            "sd": "2.9",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "9.4",
            "sd": "3.0",
            "n": "101"
          }
        }
      },
      {
        "measure": "HAMD-17",
        "day": 30,
        "form": "mean_sd",
        "location": "Table 3",
        "values": {
          "Control group (normal saline)": {
            "mean": "11.0",
            "sd": "3.8",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "9.5",
            "sd": "2.9",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "6.9",
            "sd": "2.8",
            "n": "101"
          }
        }
      },
      {
        "measure": "HAMD-17",
        "day": 90,
        "form": "mean_sd",
        "location": "Table 3",
        "values": {
          "Control group (normal saline)": {
            "mean": "7.5",
            "sd": "3.0",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "7.5",
            "sd": "3.2",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "6.5",
            "sd": "3.3",
            "n": "101"
          }
        }
      }
    ],
    "pain": [
      {
        "measure": "VAS pain",
        "day": 1,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "Control group (normal saline)": {
            "mean": "4.0",
            "sd": "0.8",
            "n": "100"
          },
          "Racemic ketamine group": {
            "mean": "3.4",
            "sd": "0.7",
            "n": "102"
          },
          "S-ketamine group": {
            "mean": "2.8",
            "sd": "0.8",
            "n": "101"
          }
        }
      }
    ],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Table 2, Complication",
        "values": {
          "Control group (normal saline)": {
            "dizziness": "13"
          },
          "Racemic ketamine group": {
            "dizziness": "11"
          },
          "S-ketamine group": {
            "dizziness": "12"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2017-06",
      "end": "2018-06"
    },
    "registration": null,
    "note": "Arm sizes from Methods and every table header; 'No patient was lost to follow-up'. HAMD-17 'Before' is the preoperative screening score (same values in Table 1); '1w' = day 7, '1 month' = day 30, '3 months' = day 90. Significance superscripts (a, b, c) dropped from Table 2 and 3 values. Pain: VAS at 3 days (S-ketamine 2.2 +/- 0.6, racemic 2.7 +/- 0.6, control 3.2 +/- 0.7) and 1 week not extracted. AEs: Table 2 'Complication, n (%)', 'Dizzy' coded dizziness, window postoperative. The printed percentages for S-ketamine (16 (15.7), 12 (11.8)) fit n = 102 and for racemic (18 (17.8), 11 (10.9), 8 (7.9)) fit n = 101, so the two ketamine columns of Table 2's complications may be swapped. Not coded: nausea 16/18/20 and vomiting 7/8/7 (S-ketamine/racemic/control). Enrollment dates from Methods ('from June 2017 to June 2018'); no registration given."
  }
]